San Carlos, CA, March 21, 2022 – FlemingMartin is pleased to announce that Natera (NASDAQ: NTRA),  a global pioneer in genetic testing and diagnostics, has hired Tera Eerkes, Ph.D., as Vice President of Oncology Product Development. Overseeing a team of senior product development professionals, Tera will provide technical leadership for the development and implementation of Natera’s full lifecycle of oncology products, as well as supply strategic vision for functional characterization of future pipeline products.

Tera comes to Natera after spending the last five-and-a-half years across an array of leadership roles at Adaptive Biotechnologies (NASDAQ: ADPT). Among her numerous accomplishments at Adaptive, Tera led pre- and post-market RA activities for the first FDA-cleared MRD product (clonoSEQ), and she built out Adaptive’s first molecular product development division.

Tera earned her Ph.D. in Molecular Biology from the University of Washington, and she received her B.S. in Computer Engineering from the University of Colorado.

NateraNatera is a worldwide genetic testing and diagnostics company that’s changing how doctors and patients manage genetic disease. Natera’s Signatera technology is the first and only circulating tumor DNA (ctDNA) surveillance tool that detects molecular residual disease (MRD) for greater clinical confidence when assessing disease recurrence or treatment response in solid tumors. To learn more, visit natera.com

 

 

Fm Logo And IconFlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards and CEOs to build successful execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. flemingmartin.com